Our consumer-facing, educational community that helps people of color take control of their health and encourages participation in clinical trials both digitally and in person.




Predictive analytics technology that tracks interest and reports on community engagement at the individual level to help organizations better plan for, execute, and learn from diversity in clinical trials.

e-DICTplus sign

Striving for equity has never been more straight forward.



Find the right locations for your next trial or health initiative. Acclinate leverages protocol, therapeutic area, location data, and information from previous efforts to gauge interest and zero in on hard-to-reach groups.

calendar icon

Predict and plan: e-DICT measures potential access and can forecast the extent to which Acclinate can reach eligible communities of color.

Community map
Communities of color photo gridBlue Color Burst
graph icon




Reach hard-to-find groups with a partnership that leverages trusted influencers, digital marketing, community events, and NOWINCLUDED channels to encourage relationship building and taking control of one’s health journey.

Graph Icon

Gain insight: Review and analyze community engagement performance metrics broken down by medium in our e-DICT platform as we focus on accessing targeted communities.


Educate & Engage

Create awareness in communities of color through online education via the NOWINCLUDED community and activation events designed to raise awareness about specific health issues.

Educate and engage

Capture the data: Whenever and however an individual engages with events and digital content, e-DICT records and interprets the action. Is a potential participant merely interested or truly invested? Acclinate helps you pinpoint the potential.

minority representation in clinical trialsPink Color Burst
engage and educate


Diversity in clinical trials ad graphicBrown Color Burst
Contact card icon




Design and roll out targeted, timely campaigns – ads, landing pages, emails, and more – to promising members of the community.

Contact card icon

Reach out with relevance. Meet people who have shown interest via clicks or follow-through at just the right moment of empowerment, education, and readiness.

Acclinate toward equity in healthcare.

Trusted by:

Johnson & JohnsonUAB MedicineBARDAinsmed

Do More for Diversity

Trial design

Trial Design

Start with insight drawn from our engaged community and plan your next trial with equity in mind from the start. Acclinate can help your organization get ahead in its diversity efforts.


Diversity Plan Enablement

Get a clear view of the health of your current initiatives and create a plan for improvement by implementing our Affective Trust Framework in your clinical trials.


Diversity Learning & Development

Increase equity acumen throughout your organization with custom training programs designed to help staff overcome challenges engaging communities of color in trial participation.

Our Clients are Changing the Face of Healthcare Research

Lightship partnered with Acclinate to increase African American representation in a phase 3 clinical trial for Alzheimer’s disease.


Acclinate’s increase in total pre-screened patients, accomplished in a third of the time.


Of those who passed the prescreener answered a call from Acclinate expressing interest in participating.

Quotation Mark

Sometimes, people do not know how to gain access to clinical trials. Our partnership with Acclinate leverage[d] their established, trusted community connections, digital platform, and app with Lightship’s robust clinical trial infrastructure and commitment to meeting participants where they are to deliver their clinical trial.

David MacMurchy

CEO, Lightship

Lightship logo
left arrow
right arrow

Frequently Asked Questions

Is Acclinate a recruitment company?

No. We’re a catalyst that turns community trust, data analysis, and insight into products that help healthcare organizations increase equity in their trials and initiatives. We do not recruit participants. Rather, we cultivate educated, empowered communities around specific health conditions and engage with them to encourage clinical trial participation. Our metrics end with pre-screened, pre-qualified candidates. Your organization then selects who to recruit.

Blue arrow

What is your pricing model?

We have three levels of pricing, based on engagement scope.

Study Level Pricing - This pricing is based on one study and is centered in a defined set of metro areas within which Acclinate will engage potential participants. Duration is defined by a timeline that begins with the first patient enrolled (FPI) and ends with the last patient enrolled (LPI) in the study. Additional metro areas can be included for an added fee.

Program Level Pricing - This pricing is based on a set of highly related studies aligned to a specific therapeutic area in which all use the same set of metro areas.  Duration is defined by a timeline that begins with the first patient enrolled (FPI) in the earliest study and ends with the last patient enrolled (LPI) in the final study.

Enterprise Level Pricing - This pricing is based on sustained engagement of a defined set of metro areas around a specific therapeutic area (TA) or set of TAs. Separate scope of work agreements are created for each study associated with the TA.

Blue arrow

What phase(s) of clinical trials do we engage in?

The earlier, the better. Our model includes three distinct stages: (1) early engagement; (2) awareness; and (3) participation. Ideally, we will require at least 3 months before the start of trial enrollment to conduct our early engagement and awareness that builds trust and gathers necessary data for our platform. Some sponsors opt to engage with us even earlier, at an indication, therapeutic area, or program level, and engage us in disease and clinical research education to prepare a pool of potentially interested participants for an upcoming trial.

If a trial has already begun enrolling, we can still conduct our work, but we would still require three months of lead time before significant potential participants can be identified and presented with the trial. As such, the longer you wait, the less value we can offer. However, our experience is that the issue of diversity is taken more seriously once an organization can quantifiably see that they are not getting adequate representation in their current trials (enough to meet FDA expectations), so no matter what, it is often a great time to discuss using Acclinate for upcoming trials. 

Blue arrow

What indications/therapeutic areas do we focus on?

Sponsors running trials for indications or therapeutic areas that disproportionately impact communities of color will find the greatest value from working with us. For example, Black Americans are twice as likely as older White Americans to suffer from Alzheimer's or another dementia. Therefore, running an Alzheimer’s trial without adequate Black representation could pose a problem for a sponsor. Specific focus areas include (but are not limited to) cancer, diabetes, sick cell, cardiovascular, kidney disease, neurological, and autoimmune disorders. In certain instances, we will also engage sponsors in rare disease trials.

Blue arrow

What communities of color does Acclinate focus on?

We are presently hyper-focused on Black/African American communities, which make up the largest percentage of our community members. However, we do serve other racial and ethnic communities as well and are currently expanding our focus communities to include Indigenous American communities, with LatinX and Hispanic communities as a fast follow.

Blue arrow

What is Acclinate’s process and what info do we need to determine if we can provide value to an organization?

Once we gain an understanding of the sponsor, indication, and high-level details of the trial, our team will conduct a preliminary assessment with an "accept or reject'' decision from our Chief Medical Lead within two business days.  If we "accept” the work, we then request the following:

  • Study protocol or synopsis, or if one doesn’t exist, the link to the study on
  • A site list, if one exists
  • Study timelines
  • Specific diversity goals and objectives, if any
  • Any additional helpful background information, including outcomes of prior community engagement efforts

Our team will then conduct a detailed population and site data analysis to determine access potential and craft a detailed approach and proposal developed within five business days of receiving the above information.

Blue arrow